B-Cure Laser

Company Overview

Snapshot

Founded in October 2007, B-Cure Laser operates with 11–50 employees, developing low-level laser therapy devices. The company went public on TASE in May 2021, raising $25.5 million.

Business overview

B-Cure Laser develops and markets portable, rechargeable, and user-friendly medical devices that provide clinical low-level laser power. These devices are designed for the rapid, noninvasive, and efficient treatment of various conditions, including pain, orthopedic issues, wounds, burns, skin problems, inflammation, and sports injuries. The company's products utilize class-one lasers and are sold over the counter, serving markets in Health Tech & Life Sciences, specifically within Medical Devices and Medical Treatment & Therapeutics.

Strategic signal

In March 2024, news emerged regarding the chairman's compensation request of nearly one million shekels for a part-time position, following a 96% collapse in the company's stock. This signals significant internal governance challenges and raises concerns about executive compensation in the context of declining company performance, indicating potential instability for investors.

Company Intelligence Q&A

What is B-Cure Laser's primary product offering?

B-Cure Laser offers a line of portable, rechargeable medical devices that provide clinical low-level laser power for the noninvasive treatment of various conditions including pain, orthopedic issues, wounds, and sports injuries.

When did B-Cure Laser go public?

B-Cure Laser went public on the TASE in May 2021.

What was a significant regulatory achievement for B-Cure Laser?

In October 2021, B-Cure Laser received approval from the Canadian Ministry of Health for its Erika Carmel device.

What is the total capital raised by B-Cure Laser?

B-Cure Laser has raised a total of $25.5 million across one funding round.

What is the employee count for B-Cure Laser?

B-Cure Laser has 11–50 employees.